42786-59-4

Basic information

• Product Name: 4-CHLORO-6-HYDRAZINO-PYRIMIDIN-5-YLAMINE
• Synonyms: 4-CHLORO-6-HYDRAZINO-PYRIMIDIN-5-YLAMINE;TIMTEC-BB SBB010419;4-Chloro-6-hydrazino-pyrimidin-5-ylamine ,97%;4-chloro-6-hydrazinylpyrimidin-5-amine
• CAS NO: 42786-59-4
• Molecular Formula: C₄H₆ClN₅
• Molecular Weight: 159.58
• EINECS: 205-525-8
• Mol File: 42786-59-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 342.7ºC at 760 mmHg
• Flash Point: 161.1ºC
• Appearance: /
• Density: 1.649g/cm3
• Vapor Pressure: 7.4E-05mmHg at 25°C
• Refractive Index: 1.766
• CAS DataBase Reference: 4-CHLORO-6-HYDRAZINO-PYRIMIDIN-5-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-HYDRAZINO-PYRIMIDIN-5-YLAMINE(42786-59-4)
• EPA Substance Registry System: 4-CHLORO-6-HYDRAZINO-PYRIMIDIN-5-YLAMINE(42786-59-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 42786-59-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C4H6ClN5/c5-3-2(6)4(10-7)9-1-8-3/h1H,6-7H2,(H,8,9,10)

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 

Downstream Products

• 15206-33-4 8-amino-7-chloro-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one 
• 99983-93-4 5-amino-4-benzylidenehydrazino-6-chloropyrimidine 

Relevant articles and documents

INHIBITORS OF CELLULAR METABOLIC PROCESSES

The invention provides inhibitor compounds of MAT2A that are useful as therapeutic agents for treating malignancies wherein the compounds have the general formula (I) : wherein ring A, ring B, ring C and, R1 are as described herein.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.